Hypertrophic cardiomyopathy Enlarged heart muscle disease
Conditions
Interventions
Not applicable.
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: MYBPC3 mutation carrier MYH7 mutation carrier Genotype-negative first degree relative of a MYBPC3 or MYH7 mutation carrier
Exclusion criteria
Exclusion criteria: >=70 years old Insulin-dependent diabetes mellitus Pregnancy Smoking Claustrophobia Pacemaker/ICD Renal insufficiency 140mmHg or diastolic >90mmHg) For the genotype negative group, no phenotype group, and mild phenotype group: the use of blood pressure medication (diuretics, beta-blockers, ACE-inhibitors, angiotensin II receptor blockers, calcium channel blockers, alpha blockers) For the HCM phenotype group: when it is unsafe to withhold from blood pressure medication (as specified above) for two days, as assessed by their own cardiologist Left ventricular outflow tract gradient > 50mmHg Aortic valve disease Left bundle branch block (History of) Obstructive coronary artery disease Chronic atrial fibrillation Hormone replacement therapy Second or third-degree AV-block, sick-sinussyndrome, prolonged QT-interval Asthma and other obstructive pulmonary diseases Previous adverse reaction to adenosine or dotarem
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Myocardial perfusion - Endothelial (dysf)function | — |
Secondary
| Measure | Time frame |
|---|---|
| - Fibrosis - Diastolic function - Strain - Volume parameters - Myocardial efficienty in advanced HCM patients (wall thickness>=15mm) who have participated in previous studies. | — |
Countries
Netherlands
Contacts
Public ContactJE Visch
Amsterdam UMC
Outcome results
None listed